| Name | Title | Contact Details |
|---|---|---|
Steven Barnard |
Vice President and Chief Technology Officer | Profile |
Carissa Rollins |
Chief Information Officer | Profile |
Jason Banthrum |
Assoc Director, Application Security and Compliance | Profile |
Alex Aravanis |
Chief Technology Officer and Head of Research and Product Development | Profile |
Alex Aravanis |
Chief Technology Officer | Profile |
Adgero Biopharmaceuticals Holdings, Inc. is a privately-held biopharmaceutical company focused on building a pipeline by advancing its proprietary late stage photodynamic therapy ("PDT") platform with broad utility for the treatment of serious oncology indications. Its lead product candidate, REM-001 Therapy, has demonstrated promising safety and efficacy in four Phase 2/3 clinical studies in patients with cutaneous metastatic breast cancer ("CMBC") who have failed radiation therapy. Use of Adgero`s existing data or the completion of a Phase 3 trial in individuals with CMBC could lead to approval of REM-001 Therapy.
We are dedicated to discovering novel biological targets and developing drugs that profoundly improve the lives of people born with rare metabolic defects who are unable to sustain basic biochemical processes necessary for life.
Biotix Holdings is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer.
BioDigital is a New York-based biomedical visualization company that is often referred to as being "Google Earth for the Human Body".